Vagus nerve stimulation for heart failure flunks a Boston Scientific clinical trial but passes a Cyberonics study, but the question is clouded by the more rigorous, sham-arm structure of the Boston Scientific trial.
The failure of Medtronic's Symplicity 3 trial doesn't mean the end of renal denervation in treated resistant hypertension, especially in Europe, but future studies face a high bar set by the Medtronic trial's sham control arm.
California's Sequent Medical begins enrolling patients in an IDE clinical trial of its Web aneurysm embolization system.
Medtech company Sequent Medical enrolled the 1st 4 patients in a new U.S. clinical trial aimed at winning FDA approval for its Web aneurysm protection implant.
The Web implant is made of a Nitinol mesh that is delivered in a "stent-like" manner and deployed into the pouch formed by an aneurysm in order to prevent blood from flowing in. The device already has approve in the European Union.
Medtech titan Medtronic enrolls the 1st patients in the AdaptResponse clinical trial to evaluate its adaptive cardiac rhythm management technology.
Medtronic (NYSE:MDT) touted the launch of its AdaptResponse trial, the largest study of its kind evaluating the company's AdaptivCRT algorithm for personalizing cardiac resynchronization therapy in treatment of heart failure.
RBC is also the exclusive provider of AdvantageRF - a portfolio of flexible mix and match solution tools for RF product developers that reduce risks, enhance reliability and sustainability, as well as accelerate time to market and lower R & D costs.